Unlike other efforts in this area, this test is an indicator of favorable, rather than unfavorable, outcome in AIDS. Further, the results are based upon in vivo data from clinically significant, albeit small, patient groups collected over a long period of time, thereby enhancing the credibility and clinical reliability of the test.

The primary advantage of this blood test is the ability to identify which patients are likely to hold the HIV infection in check, with obvious consequences in terms of patient management and emotional well-being. In addition, the invention utilizes commercially available reagents and equipment and well-known laboratory procedures, namely, immunofluorescence and flow cytometry. Thus, the invention may readily be commercialized as a kit for a diagnostic blood test that predicts good outcome in HIV-seropositive individuals. This test could also be useful as a research tool evaluating new drugs in a clinical trial.

Reference: UCLA Case No. 1992-541

US Patent Number: 5,470,701